The company said revenue for Q2 2025 rose to $2.3 billion, up 6% on both a reported and an organic basis, and earnings per share were $0.93, up 16%. On an adjusted basis, earnings per share were $1.26, also up 16%.

1. 01

   The company said revenue for Q2 2025 rose to $2.3 billion, up 6% on both a reported and an organic basis, and earnings per share were $0.93, up 16%. On an adjusted basis, earnings per share were $1.26, also up 16%.

2. 02

   Xylem said its net income margin rose 90 basis points to 9.8% in Q2, and its adjusted EBITDA margin was 21.8%, up 100 basis points year over year. It said productivity savings and price realization drove the margin expansion.

3. 03

   Xylem said it expects 2025 revenue of approximately $8.9 to $9.0 billion, up approximately 4 to 5% on a reported basis, versus 1 to 2% previously. It also expects adjusted earnings per share of $4.70 to $4.85, versus the prior guidance of $4.50 to $4.70.

4. 04

   The company reported net cash from operating activities of $338 million for the 6 months ended 2025 ($377 million a year earlier), capital expenditures of $169 million, and dividends paid of $196 million. It said cash and cash equivalents were $1,170 million as of June 30.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.